Whittier Trust Co. decreased its holdings in Eli Lilly And Co (NYSE:LLY) by 3.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,985 shares of the company’s stock after selling 500 shares during the period. Whittier Trust Co.’s holdings in Eli Lilly And Co were worth $1,660,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Trust Department MB Financial Bank N A raised its holdings in Eli Lilly And Co by 54.7% in the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after acquiring an additional 82 shares during the last quarter. Meridian Wealth Management LLC acquired a new stake in Eli Lilly And Co in the 1st quarter valued at about $38,000. WP Advisors LLC acquired a new stake in Eli Lilly And Co in the 1st quarter valued at about $38,000. Manchester Financial Inc. acquired a new stake in Eli Lilly And Co in the 2nd quarter valued at about $40,000. Finally, Larson Financial Group LLC raised its holdings in Eli Lilly And Co by 80.6% in the 1st quarter. Larson Financial Group LLC now owns 448 shares of the company’s stock valued at $58,000 after acquiring an additional 200 shares during the last quarter. Institutional investors own 79.50% of the company’s stock.
In related news, CFO Joshua L. Smiley bought 426 shares of the company’s stock in a transaction that occurred on Wednesday, June 5th. The stock was purchased at an average price of $118.03 per share, for a total transaction of $50,280.78. Following the acquisition, the chief financial officer now owns 30,410 shares of the company’s stock, valued at $3,589,292.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Michael J. Harrington sold 16,000 shares of Eli Lilly And Co stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the completion of the sale, the vice president now owns 110,300 shares of the company’s stock, valued at approximately $12,874,216. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by company insiders.
Shares of NYSE LLY traded up $1.91 during midday trading on Friday, reaching $112.42. 4,477,611 shares of the stock were exchanged, compared to its average volume of 4,018,415. The firm has a 50 day moving average of $111.04. The stock has a market cap of $107.29 billion, a PE ratio of 20.26, a P/E/G ratio of 1.95 and a beta of 0.19. The company has a quick ratio of 0.85, a current ratio of 1.12 and a debt-to-equity ratio of 5.50. Eli Lilly And Co has a twelve month low of $98.88 and a twelve month high of $132.13.
Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.45 by $0.05. The business had revenue of $5.64 billion during the quarter, compared to the consensus estimate of $5.59 billion. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 58.65%. The business’s revenue was up .9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.48 EPS. On average, research analysts predict that Eli Lilly And Co will post 5.72 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a $0.645 dividend. The ex-dividend date is Wednesday, August 14th. This represents a $2.58 annualized dividend and a yield of 2.29%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.
A number of analysts have commented on the stock. BMO Capital Markets increased their price objective on shares of Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $143.00 price objective on shares of Eli Lilly And Co in a report on Tuesday, April 30th. Barclays reiterated a “buy” rating and issued a $140.00 price objective on shares of Eli Lilly And Co in a report on Sunday, April 14th. Edward Jones upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price objective for the company in a report on Tuesday, April 23rd. Finally, TheStreet downgraded shares of Eli Lilly And Co from a “b+” rating to a “c+” rating in a report on Thursday, May 9th. Nine analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $123.49.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: What can cause a stock to outperform?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.